NASDAQ:FTSV - Forty Seven Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.93 +0.48 (+2.14 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$22.93
Today's Range$21.65 - $23.8335
52-Week Range$12.02 - $23.83
Volume176,400 shs
Average Volume113,191 shs
Market Capitalization$712.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
Previous Symbol
CUSIPN/A
Phone650-352-4150

Debt

Debt-to-Equity RatioN/A
Current Ratio11.88
Quick Ratio11.88

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees46
Outstanding Shares31,070,000
Market Cap$712.32 million
OptionableNot Optionable

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.17. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

5 brokerages have issued 1-year target prices for Forty Seven's stock. Their predictions range from $17.66 to $35.00. On average, they anticipate Forty Seven's stock price to reach $24.9320 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. HC Wainwright analysts commented, "We are initiating coverage of 12- month price target of $21.00 per share. We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and 3% terminal growth rate." (11/30/2018)
  • 2. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (11/9/2018)

Has Forty Seven been receiving favorable news coverage?

News articles about FTSV stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Forty Seven earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are some of Forty Seven's key competitors?

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 65)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 55)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 59)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

When does the company's lock-up period expire?

Forty Seven's lock-up period expires on Tuesday, December 25th. Forty Seven had issued 7,035,000 shares in its public offering on June 28th. The total size of the offering was $112,560,000 based on an initial share price of $16.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Forty Seven's major shareholders?

Forty Seven's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (1.85%), BlackRock Inc. (1.44%), JPMorgan Chase & Co. (1.11%), JPMorgan Chase & Co. (1.11%), FMR LLC (0.88%) and Vanguard Group Inc. (0.55%). Company insiders that own Forty Seven stock include Christopher J Schaepe, Lifesciences Iii LP Clarus, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Institutional Ownership Trends for Forty Seven.

Which major investors are selling Forty Seven stock?

FTSV stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP and FMR LLC. View Insider Buying and Selling for Forty Seven.

Which major investors are buying Forty Seven stock?

FTSV stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Vanguard Group Inc, Vanguard Group Inc., EcoR1 Capital LLC and United Services Automobile Association. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Lifesciences Iii LP Clarus, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Insider Buying and Selling for Forty Seven.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $22.93.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $712.32 million. Forty Seven employs 46 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel